Screener
Adaptive Biotechnologies ADPT Immune Medicine Business — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | Three Months Ended March 31, 2026 / MRD | Three Months Ended March 31, 2026 / Immune Medicine | Three Months Ended March 31, 2026 / Total | Three Months Ended March 31, 2025 / MRD | Three Months Ended March 31, 2025 / Immune Medicine(1) | Three Months Ended March 31, 2025 / Total |
|---|---|---|---|---|---|---|
| Revenue | $67,093 | $3,781 | $70,874 | $43,721 | $8,722 | $52,443 |
| Less: | ||||||
| Cost of revenue | 17,244 | * | 17,244 | 15,885 | * | 15,885 |
| Research and development | 9,226 | 13,934 | 23,160 | 9,159 | 14,488 | 23,647 |
| Sales and marketing | 24,742 | * | 24,742 | 21,413 | * | 21,413 |
| General and administrative | 12,519 | * | 12,519 | 9,502 | * | 9,502 |
| Other segment items(2) | — | 5,776 | 5,776 | — | 5,153 | 5,153 |
| Add back: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's immune medicine business — research and development expense?
- Adaptive Biotechnologies (ADPT) reported immune medicine business — research and development expense of $13.93M in Q1 2026.
- How has Adaptive Biotechnologies's immune medicine business — research and development expense changed year-over-year?
- Adaptive Biotechnologies's immune medicine business — research and development expense decreased by 3.8% year-over-year, from $14.49M to $13.93M.
- What is the long-term trend for Adaptive Biotechnologies's immune medicine business — research and development expense?
- Over 3 years (2022 to 2025), Adaptive Biotechnologies's immune medicine business — research and development expense has grown at a -20.2% compound annual growth rate (CAGR), from $109.99M to $55.86M.
- What does immune medicine business — research and development expense mean?
- This metric tracks the costs incurred by the Immune Medicine Business segment for research and development activities aimed at discovering and developing new immune-based diagnostic products. It reflects the company's investment in innovation and its commitment to advancing its clinical pipeline.
Ask your AI about Adaptive Biotechnologies's immune medicine business — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude